License and Collaboration Agreement - Additional Information (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized	$ 13,696,000	$ 13,696,000
Deferred revenue	5,530,000	5,530,000
Contract liabilities			$ 0
Contract assets	0	0	$ 0
PEACE Trial
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized	1,700,000	1,700,000
BLA Package
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue recognized	1,700,000	1,700,000
Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Non refundable payment received		$ 21,500,000
Percentage of payment for cost incurred in PIP trial		50.00%
Costs incurred in performing PIP the trial		$ 1,800,000
Additional payments received		130,000,000.0
Milestone payments received		$ 130,000,000.0
Rate of revenue share		20.00%
Upfront payment		$ 21,500,000
Transaction price		23,300
Allocation price net		12,000.0
Immedica Pharma AB | PEACE Trial
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price		7,200,000
Immedica Pharma AB | BLA Package
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price		7,200,000
Immedica Pharma AB | PIP Trial
Research And Development Arrangement Contract To Perform For Others [Line Items]
Allocated amount of transaction price		$ 4,100,000
Immedica Pharma AB | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Percentage of payment for cost incurred in PIP trial		50.00%
License Agreements | Immedica Pharma AB
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research agreement date		2021-03
Revenue recognized		$ 12,000,000.0
Deferred revenue	7,800,000	7,800,000
Deferred revenue	$ 5,500,000	$ 5,500,000